Charter Trust Co buys $9,487,530 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Charter Trust Co scooped up 1,305 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 161,380 shares of Merck & Co. which is valued at $9,487,530.Merck & Co. makes up approximately 1.07% of Charter Trust Co’s portfolio.

Other Hedge Funds, Including , Salient Trust Co Lta reduced its stake in MRK by selling 270 shares or 0.45% in the most recent quarter. The Hedge Fund company now holds 59,568 shares of MRK which is valued at $3,502,003. Merck & Co. makes up approx 0.37% of Salient Trust Co Lta’s portfolio.James Investment Research Inc boosted its stake in MRK in the latest quarter, The investment management firm added 62,435 additional shares and now holds a total of 747,627 shares of Merck & Co. which is valued at $44,124,946. Merck & Co. makes up approx 1.09% of James Investment Research Inc’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in MRK by selling 966 shares or 7.84% in the most recent quarter. The Hedge Fund company now holds 11,350 shares of MRK which is valued at $675,893. Merck & Co. makes up approx 0.11% of Gillespie Robinson Grimm Inc’s portfolio.Braver Wealth Management reduced its stake in MRK by selling 3,072 shares or 32.02% in the most recent quarter. The Hedge Fund company now holds 6,521 shares of MRK which is valued at $388,326. Merck & Co. makes up approx 0.06% of Braver Wealth Management’s portfolio.

Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.